Pharmosa Biopharm Valuation

Is 6875 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6875 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6875's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6875's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6875?

Key metric: As 6875 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6875. This is calculated by dividing 6875's market cap by their current book value.
What is 6875's PB Ratio?
PB Ratio	3.9x
Book	NT$1.90b
Market Cap	NT$7.34b

6875 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	115.8x
Enterprise Value/EBITDA	-18.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 6875's PB Ratio compare to its peers?

The above table shows the PB ratio for 6875 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6.3x
6617 Gongwin Biopharm Holdings	4.4x	n/a	NT$14.0b
6733 BioGend Therapeutics	5.1x	n/a	NT$4.5b
6541 Tanvex BioPharma	9.7x	n/a	NT$11.2b
6794 UnicoCell Biomed	6.1x	n/a	NT$4.3b
6875 Pharmosa Biopharm	3.9x	n/a	NT$7.3b

Price-To-Book vs Peers: 6875 is good value based on its Price-To-Book Ratio (3.9x) compared to the peer average (6.3x).

Price to Book Ratio vs Industry

How does 6875's PB Ratio compare vs other companies in the TW Biotechs Industry?

0 Companies	Price / Book	Estimated Growth	Market Cap

No more companies available in this PB range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 6875 is expensive based on its Price-To-Book Ratio (3.9x) compared to the TW Biotechs industry average (3.8x).

Price to Book Ratio vs Fair Ratio

What is 6875's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6875 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	3.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6875's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

RBC Bioscience

NT$254.3m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.60

-0.5%

29.8%

YungShin Global Holding

NT$15.4b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.90

8.2%

27.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%